-
公开(公告)号：EP4059502A1
公开(公告)日：2022-09-21
申请号：EP20887321.6
申请日：2020-11-11
摘要： Provided is an orally disintegrating tablet comprising brexpiprazole or a salt thereof that rapidly disintegrates in the oral cavity while having hardness suitable for practical use.
More specifically, provided is an orally disintegrating tablet comprising (A) brexpiprazole or a salt thereof, (B) D-mannitol, (C) partially pregelatinized starch, and (D) a lubricant.-
公开(公告)号：EP1300160A1
公开(公告)日：2003-04-09
申请号：EP01932213.0
申请日：2001-05-23
发明人： TOMOHIRA, Yuso , MUKAI, Tadashi , KASHIMOTO, Minoru , NAGASAWA, Masakazu , ICHIBA, Tetsuroh , KURIBAYASHI, Daisuke , OKA, Yoshikazu , TOGUCHI, Hajime
CPC分类号： A61K9/2054 , A61K9/2013 , A61K47/02 , A61K47/20
摘要： Disclosed is a method for stabilizing a solid pharmaceutical preparation containing a pharmacological substance and sodium lauryl sulfate, the method comprising incorporating into the preparation at least one member selected from the group consisting of neutral salts, basic salts and basic substances. The preparation containing sodium lauryl sulfate prepared by the method of the invention has superior performance, including high storage stability, suppression of discoloration and deterioration, and prevention of change in its properties, such as the dissolution rate of pharmacological substance from the preparation.
摘要翻译： 公开了一种稳定含有药理学物质和十二烷基硫酸钠的固体药物制剂的方法，该方法包括将至少一种选自中性盐，碱性盐和碱性物质的成分掺入制剂中。 通过本发明方法制备的含有十二烷基硫酸钠的制剂具有优异的性能，包括高储存稳定性，抑制变色和变质，以及防止其制备物质的药理学溶解速度等性质的改变。
-
公开(公告)号：EP1300160B1
公开(公告)日：2014-03-12
申请号：EP01932213.0
申请日：2001-05-23
发明人： TOMOHIRA, Yuso , MUKAI, Tadashi , KASHIMOTO, Minoru , NAGASAWA, Masakazu , ICHIBA, Tetsuroh 59-15, Aza Sumiyoshikaitaku , KURIBAYASHI, Daisuke , OKA, Yoshikazu , TOGUCHI, Hajime
IPC分类号： A61K31/4709 , A61K47/02 , A61K47/12 , A61K47/20 , A61K9/20
CPC分类号： A61K9/2054 , A61K9/2013 , A61K47/02 , A61K47/20
-
公开(公告)号：EP1162973A1
公开(公告)日：2001-12-19
申请号：EP00909776.7
申请日：2000-03-21
CPC分类号： A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1652 , A61K9/2081 , A61K9/5042 , A61K9/5084 , A61K31/4709 , Y10S514/951 , Y10S514/952 , Y10S514/96 , Y10S514/961 , Y10S514/962 , Y10S514/963 , Y10S514/964
摘要： Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.
-
公开(公告)号：EP1162973B1
公开(公告)日：2005-05-25
申请号：EP00909776.7
申请日：2000-03-21
CPC分类号： A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1652 , A61K9/2081 , A61K9/5042 , A61K9/5084 , A61K31/4709 , Y10S514/951 , Y10S514/952 , Y10S514/96 , Y10S514/961 , Y10S514/962 , Y10S514/963 , Y10S514/964
摘要： Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.
-
-
-
-
搜索结果
5 条记录 (耗时 0.011 秒)
